Abstract: The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (?4?1?1), laminin 511 (?5?1?1), laminin 521 (?5?2?1), or fragments of these.

Abstract: The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.

Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.

Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.

Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.

Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.

Abstract: The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (?5?1?1), laminin 521 (?5?2?1), or a fragment of these.

Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.

Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.

Abstract: The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) ? signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.

Abstract: Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-? (TGF-?) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-? signal is Fuchs' corneal endothelial dystrophy.

Abstract: The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-? (TGF-?) signal and/or extracellular matrix (ECM).

Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

Abstract: Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-? (TGF-?) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-? signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.

Abstract: The present disclosure provides a method of preserving corneal endothelial cells at a high cell survival rate. The present disclosure provides a method of preserving corneal endothelial cells and/or corneal endothelium-like cells, comprising preserving the corneal endothelial cells and corneal endothelium-like cells in a container with a bottom area of at least about 0.7 cm2. Accordingly to the present invention, corneal endothelial cells can be preserved at a high cell survival rate. Corneal endothelial cells preserved in this manner have functions of normal corneal endothelial cells. Such cells can also be used as cells for treating a corneal endothelial disease or the like.

Abstract: The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-? (TGF-?) signal and/or extracellular matrix (ECM).

Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

Abstract: The present disclosure provides a formulation having improved solubility and/or stability of emricasan. In one embodiment, the present disclosure provides a formulation containing (i) emricasan or a derivative thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, (ii) a nonionic surfactant including a polyoxyethylene group, and (iii) a buffering agent that maintains the pH at about 4.5 to about 8.5. The present disclosure also provides a composition in the form of powder for preparing such a formulation at the time of use.

Abstract: The present disclosure provides a composition and method for preserving ocular cells. More specifically, the present disclosure provides a composition for preserving ocular cells, or culturing the cells after preservation, comprising albumin and dimethyl sulfoxide, and a cell formulation comprising the ocular cells, albumin, and dimethyl sulfoxide, and a treatment/prevention method using the same. The present disclosure also provides a method of preserving corneal endothelial cells, comprising suspending ocular cells in the composition to provide a suspension and freezing the suspension. In some embodiments, ocular cells are corneal cells (e.g., corneal endothelial cells).

Abstract: Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-? (TGF-?) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-? signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.